Last reviewed · How we verify
Sodium warfarin
Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by antagonizing vitamin K epoxide reductase, thereby reducing thrombin generation and preventing blood clot formation.
Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by antagonizing vitamin K epoxide reductase, thereby reducing thrombin generation and preventing blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Mechanical heart valve thromboprophylaxis.
At a glance
| Generic name | Sodium warfarin |
|---|---|
| Also known as | Vitamin K antagonists, Oral anticoagulants |
| Sponsor | University of Padova |
| Drug class | Vitamin K antagonist (coumarin anticoagulant) |
| Target | Vitamin K epoxide reductase complex 1 (VKORC1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Warfarin is a coumarin anticoagulant that acts as a vitamin K antagonist. It inhibits the enzyme vitamin K epoxide reductase, which is essential for the carboxylation and activation of vitamin K-dependent clotting factors. This results in decreased synthesis of functional factors II, VII, IX, and X, prolonging the prothrombin time and reducing the risk of thromboembolism.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention
- Mechanical heart valve thromboprophylaxis
- Post-myocardial infarction thromboprophylaxis
Common side effects
- Bleeding (major and minor)
- Warfarin-induced skin necrosis
- Nausea
- Alopecia
- Rash
Key clinical trials
- A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF (PHASE4)
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
- SWITCH: Apixaban vs Vitamin K in HM3 (PHASE3)
- A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer (PHASE1)
- Personalized Medicine Decision-Making in a Virtual Clinical Setting
- The PEERLESS II Study (NA)
- Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation (NA)
- LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |